Clinical Trials · NCT07463846
A Study to Evaluate ALN-2232 in Participants With Obesity
- Phase
- Phase 1/Phase 2
- Recruitment status
- Recruiting
- Sponsor
- Alnylam Pharmaceuticals
- Enrollment
- 156
- Start date
- Mar 2026
- Locations
- 1 site, Canada
- Primary endpoint
- Part A: Frequency of Adverse Events (AEs)